Success Metrics

Clinical Success Rate
57.1%

Based on 4 completed trials

Completion Rate
57%(4/7)
Active Trials
0(0%)
Results Posted
150%(6 trials)
Terminated
3(43%)

Phase Distribution

Ph phase_1
1
14%
Ph phase_2
3
43%
Ph phase_3
3
43%

Phase Distribution

1

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution7 total trials
Phase 1Safety & dosage
1(14.3%)
Phase 2Efficacy & side effects
3(42.9%)
Phase 3Large-scale testing
3(42.9%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

57.1%

4 of 7 finished

Non-Completion Rate

42.9%

3 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Completed(4)
Terminated(3)

Detailed Status

Completed4
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
57.1%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (14.3%)
Phase 23 (42.9%)
Phase 33 (42.9%)

Trials by Status

completed457%
terminated343%

Recent Activity

0 active trials
Showing 5 of 7
completedphase_2

A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

NCT01998841
completedphase_2

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

NCT03977584
terminatedphase_3

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

NCT02670083
terminatedphase_3

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

NCT03114657
terminatedphase_3

An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

NCT03491150
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT01998841Phase 2

A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort

Completed
NCT03977584Phase 2

Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease

Completed
NCT02670083Phase 3

A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).

Terminated
NCT03114657Phase 3

A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)

Terminated
NCT03491150Phase 3

An Open-Label Crenezumab Study in Participants With Alzheimer's Disease

Terminated
NCT01723826Phase 2

A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab

Completed
NCT02427243Phase 1

A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7